Vitespen

Drug Profile

Vitespen

Alternative Names: Cancer vaccine heat shock protein peptide complex-96 - Agenus; Cancer vaccine HSPPC-96; G-100; G-200; Heat shock protein peptide complex 96 cancer vaccine - Agenus; Heat-shock protein-based vaccine; HSPPC-96; NP-150; Oncophage; Prophage series G-100 vaccine; Prophage series G-200 vaccine; Prophage™ heat shock protein-based autologous vaccine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fordham University; Mount Sinai School of Medicine
  • Developer Agenus; University of Texas Health Science Center at Houston
  • Class Antineoplastics; Cancer vaccines; Heat shock proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma; Glioma; Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Glioma; Malignant melanoma
  • No development reported Brain cancer; Colorectal cancer; Gastric cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer
  • Discontinued Chronic myeloid leukaemia; Leukaemia; Sarcoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain-cancer(In children, In infants) in USA (Intradermal)
  • 17 Jan 2017 Agenus and National Cancer Institute plan a phase II trial of vitespen and pembrolizumab for Glioma (Combination therapy, Newly diagnosed) in USA
  • 08 Feb 2016 The University of Texas Health Science Center and Agenus withdraw a phase I/II trial for Malignant melanoma (Combination therapy, Late-stage disease) in USA (NCT02452281)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top